CoreCivic lifts 2026 outlook after earnings beat

CoreCivic ((CXW)) has held its Q1 earnings call. Read on for the main highlights of the call.

CoreCivic’s latest earnings call struck a notably upbeat tone, with management emphasizing robust financial momentum, strong federal demand and successful reactivation of previously idled facilities. While they acknowledged policy-driven volatility in immigration detention and some pressure from lower U.S. Marshals volumes, executives argued that raised guidance, an accretive acquisition and disciplined capital allocation outweigh near-term headwinds.

Strong financial outperformance

CoreCivic posted adjusted EBITDA of $110.1 million in the first quarter of 2026, up 36% from a year earlier, and adjusted EPS of $0.40, a 74% jump even before M&A effects. Normalized funds from operations per share climbed 44% to $0.65, GAAP EPS reached $0.38 and the company beat Wall Street expectations by $0.12 per share on earnings and by $13.3 million on adjusted EBITDA.

Federal revenue surge led by ICE contracts

Federal revenue grew 48% year over year, powered by a 96.2% increase in revenue from U.S. Immigration and Customs Enforcement, adding $128.1 million in the quarter. ICE populations in CoreCivic’s care rose by about 4,500 individuals, roughly a 45% increase since early 2025, leaving the company managing around 24% of total ICE detainees at quarter end.

Organic facility activations boost growth

The company reactivated five previously idle facilities and reported $100.8 million in first quarter revenue from four of them, annualizing at roughly 93% of expected stabilized levels. Key sites like California City and Diamondback housed 1,817 and 735 individuals respectively, while the approved reactivation of the Midwest Regional Reception Center is expected to add $0.05 to $0.06 of incremental EPS over the rest of 2026.

Clinical Solutions deal broadens recurring revenue

CoreCivic closed the acquisition of Clinical Solutions Pharmacy for about $148 million, funded with cash and borrowings under its revolving credit facility, in a move aimed at expanding its healthcare adjacencies. CSP serves more than 600 correctional facilities across 28 states, fills about 60,000 prescriptions daily and is projected to generate $215 million to $230 million of revenue in 2026 while contributing $0.03 to $0.05 per share after financing costs.

Guidance raised on stronger cash generation

Management raised full year 2026 guidance, now targeting adjusted diluted EPS of $1.53 to $1.63 and adjusted EBITDA of $453.8 million to $461.8 million, up from prior ranges. The outlook reflects the first quarter earnings beat, contributions from the Midwest Regional restart and the CSP deal, with adjusted funds from operations projected between $250.4 million and $264.9 million to support ongoing capital deployment.

Shareholder capital returns remain a priority

CoreCivic continued to lean into buybacks, repurchasing 2.3 million shares for $44.7 million in the first quarter alone and bringing total repurchases since 2022 to 28.1 million shares. Those buybacks, executed at an average price of $15.82, still leave $255.8 million available under the current authorization, and management signaled that repurchases remain a preferred use of cash when shares trade at attractive levels.

Liquidity and leverage under active management

The company ended March with $209.7 million of cash and $131.3 million of remaining revolver capacity, for total liquidity of roughly $341 million, against a $425 million revolver balance. Net debt to adjusted EBITDA stood at 2.8 times on a trailing basis, and after quarter end CoreCivic entered a $100 million 364 day term loan to replenish revolving capacity while it balances acquisitions, buybacks and debt reduction.

Margins stable despite increased activity

Operating margins in the Safety and Community segments held firm, with combined margins rising to 24% from 23.6% a year earlier even as facilities ramped up. When excluding the impact of employee retention credits, operating margins were roughly 23% in both periods, suggesting that CoreCivic is absorbing activation costs without sacrificing underlying profitability.

ICE population swings pose near term drag

Nationwide ICE detention levels climbed to about 70,800 in late January before falling by roughly 10,500 people by early April, driving CoreCivic’s ICE counts down by about 3,000 from the peak. Management warned that this volatility will pressure second quarter results, guiding to a sequential per share decline of roughly $0.06 to $0.07 and trimming full year EPS expectations by $0.09 to $0.15 due to lower ICE populations.

U.S. Marshals revenue under pressure

While federal ICE business surged, revenue from the U.S. Marshals Service declined by $12.2 million year over year as average daily populations fell by about 1,360 individuals. This drop partially offset ICE driven gains and underscores CoreCivic’s sensitivity to shifts in federal law enforcement demand across different agencies.

Government policy and funding risks persist

Executives highlighted the impact of a partial federal government shutdown, leadership changes at the Department of Homeland Security and the temporary redeployment of ICE agents to transportation security, all of which disrupted enforcement and detention flows. They also acknowledged that potential policy moves, such as the government owning more detention assets or repurposing warehouses, could reshape contracting opportunities for private operators over time.

Short term financing mix and leverage considerations

CoreCivic’s capital structure leans on short duration financing, with a sizable revolver draw and the newly added 364 day term loan underscoring its near term funding needs. Management argued that leverage at 2.8 times net debt to adjusted EBITDA is manageable, but investors will be watching how the company balances further buybacks and acquisitions against the goal of maintaining a prudent balance sheet.

State contracts and facility transition effects

On the state side, revenue was hurt by the transition of the Trousdale facility in Tennessee, which weighed on first quarter results but is expected to normalize in coming quarters. Management also noted that legal and permitting delays related to a special use permit slowed the ramp of the Midwest Regional facility, and that these timing issues were not fully embedded in earlier guidance.

One off costs cloud year over year comparisons

Earnings also reflected $2.4 million of merger and acquisition expenses tied to the Clinical Solutions Pharmacy deal and higher general and administrative costs from executive transition activities. Additionally, the final collection of an employee retention credit in the quarter affected adjusted EBITDA, meaning investors should strip out these items when assessing the run rate of CoreCivic’s earnings power.

Uncertain path for potential warehouse conversions

Management addressed public discussions about converting warehouses into detention centers, but stressed that any such strategy would face significant hurdles, including community resistance, infrastructure needs and permitting complexity. That uncertainty leaves the competitive environment for future detention bed demand somewhat opaque, even as CoreCivic positions its owned facilities as a ready made alternative.

Guidance and outlook emphasize growth with caution

Looking ahead, CoreCivic’s raised guidance incorporates a mix of tailwinds and offsets, including contributions from Midwest Regional and Clinical Solutions and a meaningful drag from lower ICE populations. The outlook assumes maintenance capital spending of $60 million to $70 million, additional capital for facility activations, a 25% to 30% tax rate and continued share repurchases, while explicitly excluding any benefit from yet to be awarded contracts or future acquisitions.

CoreCivic’s earnings call painted a picture of a company benefiting from strong federal demand, disciplined cost control and strategic diversification, yet still tethered to policy swings and short term financing dynamics. For investors, the raised guidance, ongoing buybacks and accretive acquisition program signal confidence in the company’s trajectory, but the inherent volatility in government detention contracts remains a central risk to watch.